Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.
about
Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapyPrevention of Hepatitis B reactivation in the setting of immunosuppressionHepatitis B virus reactivation with a rituximab-containing regimenHepatitis B virus reactivation with rituximab-containing regimenHematologic safety of breast cancer chemotherapies in patients with hepatitis B or C virus infection.Immunorestitution disease involving the innate and adaptive response.Antiviral treatment in chronic infection with hepatitis B virus.Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management.Complement fixing hepatitis B core antigen immune complexes in the liver of patients with HBs antigen positive chronic disease.Natural history of the HBsAg carrier.Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.S-phase arrest after vincristine treatment may promote hepatitis B virus replicationThe compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder systemProphylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy.Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation.Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapyTreatment of a case of fulminant hepatic failure with continuous infusion of prostaglandin (PGE1).Effect of short-term prednisolone therapy in patients with severe chronic type B hepatitisLong-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients.Management of hepatitis B reactivation in patients receiving cancer chemotherapy.Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours.Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapyFulminant hepatitis following chemotherapy treatment for breast cancerProphylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis.Acute hepatic failure in children.Medical virology of hepatitis B: how it began and where we are nowHepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experienceHepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.Occult hepatitis B: clinical implications and treatment decisions.Hepatitis B virus reactivation associated with anti-neoplastic therapy.Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): a Systematic Review and Meta-analysis.Fulminant hepatic failure in nephrotic syndrome related to withdrawal of immunosuppressive therapy.Hepatitis-B: a review.Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?Prevention of HBV reactivation in patients treated with biologic agents.Hepatitis B Virus Seroprevalence Among Children With Cancer in Sudan.Rituximab administration and reactivation of HBV.Hepatitis B reactivation after chemotherapy: two decades of clinical research.Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies.
P2860
Q24240881-2AAAB407-8B58-464A-B1A2-B388FF6E0EFCQ26747023-6A76F729-7EE2-4C75-A50B-DBD51904F07FQ26785963-F6C16A6A-6D9B-4CEF-B973-D5B5E35496E7Q26830484-68487C18-BBE0-4082-AFA9-A6FAB5919502Q33400777-92A91DBA-A23B-4269-925A-3F48A382080FQ33958197-AD374334-9C89-4672-B02C-2DDF036D745AQ34284781-6B8C7341-B17E-41EE-BB9C-CC1160813ED7Q34394777-47006762-6CF6-4769-A6ED-4BF0AE0BB4E2Q34472185-6B9E698A-394C-4BD1-8463-B0A30F9B8B6FQ34527022-6C33A87C-A58B-4AB4-8C21-B6011A37B253Q34734311-5DE8E6E8-601B-4CCB-BA16-155F15629C61Q35045736-3BCE26E8-3D26-4DD6-9E49-E6C77DFFB795Q35057889-1777396B-FF67-4287-ABF3-5C3757567F68Q35152610-83FD14B3-6B5D-4556-AD2B-C950A36D54B1Q35210407-AB8F498B-3DF1-486E-973A-E38137057B36Q35597892-465804F9-D549-4832-A64B-9A3D318BFE07Q35948414-FAD8BFC1-7003-4CE1-AE61-A0A217C6D6E5Q35948474-788D5DBC-7CD3-4788-8664-A8E9CD8A7EBDQ36213915-47824E87-A8FB-4B58-8054-5A49846656B5Q36220459-D8181B45-7C59-48C0-90D7-DB35C6DDDD57Q36641166-BC3951FA-024C-4B83-AF37-1D300E3B21C2Q36694864-69496869-C28A-466E-BA41-A774359554B3Q36704509-5206E453-2699-4065-80CB-7C6E29CE7EFCQ36957087-516BA7A3-A2BD-4012-BD6B-4E5014E3A105Q36988740-457129F2-2E5D-4BD8-B214-6F557E89DA68Q37059714-0A0C3743-8CB5-4653-88DB-B994FD1D6D24Q37205405-AC53E45F-3919-470A-A764-63AA91722F83Q37764963-7539CE21-BE6E-4C8E-BCB7-E71E3498C87BQ37798473-61304F10-1250-4E47-A6A8-47B01397DC69Q38047362-DDBE5651-C455-403D-A2F0-0AE864E42F0CQ38611674-3C929296-D3C2-4616-8521-0762F93EDE79Q39174492-2C757DF6-ABA4-4255-8A04-4ED676F4DB6DQ39394508-F5D7DBB6-7F1D-4A6C-B62C-E94E8D0579ACQ40484172-D09C6F2D-194E-46A4-8786-126A1AD0E134Q40688823-CAAAFBB6-CCC9-459D-8B3B-282257F1430BQ40830395-66EC7D05-AC1B-43BF-B387-64A6EC274B8CQ40997112-6EDD87BF-45E4-4F47-BE1B-C0A63966309AQ41215683-C05EED5A-0F16-484B-9E4E-CE7D0540A34FQ42590960-E6BA67B7-A9D3-49A5-8041-AF78D69992A6Q43034255-59DFDCEF-A9F6-4C50-BD4F-4CA2E672A1BB
P2860
Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.
description
1975 nî lūn-bûn
@nan
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
1975年论文
@zh
1975年论文
@zh-cn
name
Fulminant hepatic failure in l ...... wal of cytotoxic drug therapy.
@en
Fulminant hepatic failure in l ...... wal of cytotoxic drug therapy.
@nl
type
label
Fulminant hepatic failure in l ...... wal of cytotoxic drug therapy.
@en
Fulminant hepatic failure in l ...... wal of cytotoxic drug therapy.
@nl
prefLabel
Fulminant hepatic failure in l ...... wal of cytotoxic drug therapy.
@en
Fulminant hepatic failure in l ...... wal of cytotoxic drug therapy.
@nl
P2093
P1433
P1476
Fulminant hepatic failure in l ...... wal of cytotoxic drug therapy.
@en
P2093
A J Zuckerman
A L Eddleston
R M Galbraith
R Williams
P304
P356
10.1016/S0140-6736(75)90897-1
P407
P577
1975-09-01T00:00:00Z